

17. A method according to claim 11, wherein during the period lamivudine as the nucleoside analogue is administered in a dose from 50 to 150 mg per day.
18. A method according to claim 11, wherein during the period interferon- α is administered in a dose from 30 megaUnits to 15 megaUnits per week.
19. A kit of parts, comprising at least a first container and a second container, wherein the first container comprises a nucleoside analogue and the second container comprises interferon- α .
20. A kit of parts according to claim 19, wherein the nucleoside analogue is lamivudine, adefovir, or entecavir.--

Remarks


Claims 11-20 are pending in this application. Support for these claims appears in the specification and original claims 1-10.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:



Steven J. Scott
Reg. No. 43,911

Date: April 26, 2001